Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?
Line Lundegaard Bang,
Lone Wulff Madsen,
Rune Micha Pedersen,
Anna Christine Nilsson,
Isik Somuncu Johansen,
Thomas Emil Andersen
Affiliations
Line Lundegaard Bang
Department of Clinical Microbiology, Odense University Hospital, and Research Unit of Clinical Microbiology, University of Southern Denmark, Odense, Denmark
Lone Wulff Madsen
Department of Infectious Diseases, Odense University Hospital and Research Unit for Infectious Diseases, University of Southern Denmark, Odense, Denmark; Unit for Infectious Diseases, Department of Medicine, Sygehus Lillebælt, Kolding, Denmark; Department of Regional Health Research, University of Southern Denmark, Denmark
Rune Micha Pedersen
Department of Clinical Microbiology, Odense University Hospital, and Research Unit of Clinical Microbiology, University of Southern Denmark, Odense, Denmark
Anna Christine Nilsson
Department of Clinical Immunology, Odense University Hospital, and Research Unit for Clinical Immunology, University of Southern Denmark, Odense, Denmark
Isik Somuncu Johansen
Department of Infectious Diseases, Odense University Hospital and Research Unit for Infectious Diseases, University of Southern Denmark, Odense, Denmark
Thomas Emil Andersen
Corresponding author.; Department of Clinical Microbiology, Odense University Hospital, and Research Unit for Clinical Microbiology, University of Southern Denmark, Odense, Denmark
